AGY2

AGY2 is a novel pyrimidine nucleoside analog and a derivative of 5-fluorouracil (5-FU), specifically a carbamate-modified version of Tegafur (1-(tetrahydrofuran-2-yl)-5-fluorouracil). Developed by researchers at Florida A&M University, it is designed to improve the metabolic stability and therapeutic efficacy of 5-FU in the treatment of pancreatic cancer. AGY2 acts as an antimetabolite, inhibiting DNA synthesis and inducing apoptosis through the upregulation of p53 and BAX proteins and the downregulation of PARP. In preclinical studies, AGY2 demonstrated superior anticancer activity compared to 5-FU and AGY1 in MiaPaCa-2 and PANC-1 cell lines, as well as in organoid and spheroid models. It has also been formulated into EGFR-conjugated liposomal drug delivery systems (AGY2-EGFR LDDS) to enhance targeting and reduce systemic toxicity in EGFR-positive pancreatic cancer.

Other names

heptyl (5-fluoro-2-oxo-1-(tetrahydrofuran-2-yl)-1,2-dihydropyrimidine-4-yl) carbamate